France's Virbac sees full-year drop in sales as lockdowns hurt demand

Veterinarian pharmaceutical company Virbac said on Monday it expected a drop in sales for the full-year 2020, amid pressure on supplies due to the coronavirus crisis and uncertainty about demand.

July 20 (Reuters) - Veterinarian pharmaceutical company Virbac VIRB.PA said on Monday it expected a drop in sales for the full-year 2020, amid pressure on supplies due to the coronavirus crisis and uncertainty about demand.

The French company now forecasts a decline in revenue of between -3% and 0% for the year at constant exchange rates.

The group, which makes food, shampoos and medicines for pets and farm animals, posted second-quarter sales of 230.6 million euros ($264 million), a decline of 6.4% compared to 246.1 million euros in the year-ago period.

($1 = 0.8743 euros)

(Reporting by Linda Pasquini; Editing by Edmund Blair)

((linda.pasquini@thomsonreuters.com; +48 58 7785261;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More